86. D. Prim, F. Rebeaud, V. Cosandey, R. Marti, P. Passeraub, M.E. Pfeifer, ADIBO-based
“click” chemistry for diagnostic peptide micro-array fabrication: physicochemical and assay
characteristics. Molecules 18, 9833–9849 (2013)
87. H. Hong, K. Yang, Y. Zhang, J.W. Engle, L. Feng, Y. Yang et al., In vivo targeting and
imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS
Nano. 6, 2361–2370 (2012)
88. H. Hong, Y. Zhang, J.W. Engle, T.R. Nayak, C.P. Theuer, R.J. Nickles et al., In vivo
targeting and positron emission tomography imaging of tumor vasculature with
66
Ga-labeled
nano-graphene. Biomaterials 33, 4147–4156 (2012)
89. D. Yang, L. Feng, C.A. Dougherty, K.E. Luker, D. Chen, M.A. Cauble et al., In vivo
targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide.
Biomaterials 104, 361–371 (2016)
90. S. Shi, K. Yang, H. Hong, F. Chen, H.F. Valdovinos, S. Goel et al., VEGFR targeting leads
to significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials 39, 39–
46 (2015)
91. H.J. Im, C.G. England, L.Z. Feng, S.A. Graves, R. Hernandez, R.J. Nickles et al.,
Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated
nanoparticles in peripheral arterial disease. ACS Appl. Mater. Interfaces 8, 17955–17963
(2016)
92. C.G. England, H.J. Im, L.Z. Feng et al., Re-assessing the enhanced permeability and
retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. Biomaterials 100, 101–109 (2016)
93. B. Cornelissen, S. Able, V. Kersemans, P.A. Waghorn, S. Myhra, K. Jurkshat et al.,
Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT
imaging of HER2-positive tumors. Biomaterials 34, 1146–1154 (2013)
94. Y. Fazaeli, O. Akhavan, R. Rahighi, M.R. Aboudzadeh, E. Karimi, H. Afarideh, In vivo
SPECT imaging of tumors by
198,199 Au-labeled graphene oxide nanostructures. Mater. Sci.
Eng. C Mater. Biol. Appl. 45, 196–204 (2014)
95. K. Yang, J.M. Wan, S.A. Zhang, Y.J. Zhang, S.T. Lee, Z.A. Liu, In vivo pharmacokinetics,
long-term biodistribution, and toxicology of PEGylated graphene in mice. ACS Nano. 5,
516–522 (2011)
96. F.M. Lu, Z. Yuan, PET/SPECT molecular imaging in clinical neuroscience: recent advances
in the investigation of CNS diseases. Quant. Imaging Med. Surg. 5, 433–447 (2015)
97. J. Song, X. Yang, O. Jacobson, L. Lin, P. Huang, G. Niu et al., Sequential drug release and
enhanced photothermal and photoacoustic effect of hybrid reduced graphene oxide-loaded
ultrasmall gold nanorod vesicles for cancer therapy. ACS Nano. 9, 9199–9209 (2015)
98. T.H. Tran, H.T. Nguyen, T.T. Pham, J.Y. Choi, H.G. Choi, C.S. Yong et al., Development
of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug
resistance in cancer. ACS Appl. Mater. Interfaces 7, 28647–28655 (2015)
99. L. Zhou, L. Zhou, S. Wei, X. Ge, J. Zhou, H. Jiang et al., Combination of chemotherapy and
photodynamic therapy using graphene oxide as drug delivery system. J. Photochem.
Photobiol. B 5(135), 7–16 (2014)
100. B. Lewis, E. Chalhoub, C. Chalouhy, O. Sartor, Radium-223 in bone-metastatic prostate
cancer: current data and future prospects. Oncology 29, 483–488 (2015)
101. D.A. Scheinberg, M.R. McDevitt, Actinium-225 in targeted alpha-particle therapeutic
applications. Curr. Radiopharm. 4, 306–320 (2011)
102. L. Chen, X. Zhong, X. Yi, M. Huang, P. Ning, T. Liu et al., Radionuclide
131 I labeled
reduced graphene oxide for nuclear imaging guided combined radio- and photothermal
therapy of cancer. Biomaterials 66, 21–28 (2015)
4 Graphene-Based Nanomaterials
103
“click” chemistry for diagnostic peptide micro-array fabrication: physicochemical and assay
characteristics. Molecules 18, 9833–9849 (2013)
87. H. Hong, K. Yang, Y. Zhang, J.W. Engle, L. Feng, Y. Yang et al., In vivo targeting and
imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS
Nano. 6, 2361–2370 (2012)
88. H. Hong, Y. Zhang, J.W. Engle, T.R. Nayak, C.P. Theuer, R.J. Nickles et al., In vivo
targeting and positron emission tomography imaging of tumor vasculature with
66
Ga-labeled
nano-graphene. Biomaterials 33, 4147–4156 (2012)
89. D. Yang, L. Feng, C.A. Dougherty, K.E. Luker, D. Chen, M.A. Cauble et al., In vivo
targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide.
Biomaterials 104, 361–371 (2016)
90. S. Shi, K. Yang, H. Hong, F. Chen, H.F. Valdovinos, S. Goel et al., VEGFR targeting leads
to significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials 39, 39–
46 (2015)
91. H.J. Im, C.G. England, L.Z. Feng, S.A. Graves, R. Hernandez, R.J. Nickles et al.,
Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated
nanoparticles in peripheral arterial disease. ACS Appl. Mater. Interfaces 8, 17955–17963
(2016)
92. C.G. England, H.J. Im, L.Z. Feng et al., Re-assessing the enhanced permeability and
retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. Biomaterials 100, 101–109 (2016)
93. B. Cornelissen, S. Able, V. Kersemans, P.A. Waghorn, S. Myhra, K. Jurkshat et al.,
Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT
imaging of HER2-positive tumors. Biomaterials 34, 1146–1154 (2013)
94. Y. Fazaeli, O. Akhavan, R. Rahighi, M.R. Aboudzadeh, E. Karimi, H. Afarideh, In vivo
SPECT imaging of tumors by
198,199 Au-labeled graphene oxide nanostructures. Mater. Sci.
Eng. C Mater. Biol. Appl. 45, 196–204 (2014)
95. K. Yang, J.M. Wan, S.A. Zhang, Y.J. Zhang, S.T. Lee, Z.A. Liu, In vivo pharmacokinetics,
long-term biodistribution, and toxicology of PEGylated graphene in mice. ACS Nano. 5,
516–522 (2011)
96. F.M. Lu, Z. Yuan, PET/SPECT molecular imaging in clinical neuroscience: recent advances
in the investigation of CNS diseases. Quant. Imaging Med. Surg. 5, 433–447 (2015)
97. J. Song, X. Yang, O. Jacobson, L. Lin, P. Huang, G. Niu et al., Sequential drug release and
enhanced photothermal and photoacoustic effect of hybrid reduced graphene oxide-loaded
ultrasmall gold nanorod vesicles for cancer therapy. ACS Nano. 9, 9199–9209 (2015)
98. T.H. Tran, H.T. Nguyen, T.T. Pham, J.Y. Choi, H.G. Choi, C.S. Yong et al., Development
of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug
resistance in cancer. ACS Appl. Mater. Interfaces 7, 28647–28655 (2015)
99. L. Zhou, L. Zhou, S. Wei, X. Ge, J. Zhou, H. Jiang et al., Combination of chemotherapy and
photodynamic therapy using graphene oxide as drug delivery system. J. Photochem.
Photobiol. B 5(135), 7–16 (2014)
100. B. Lewis, E. Chalhoub, C. Chalouhy, O. Sartor, Radium-223 in bone-metastatic prostate
cancer: current data and future prospects. Oncology 29, 483–488 (2015)
101. D.A. Scheinberg, M.R. McDevitt, Actinium-225 in targeted alpha-particle therapeutic
applications. Curr. Radiopharm. 4, 306–320 (2011)
102. L. Chen, X. Zhong, X. Yi, M. Huang, P. Ning, T. Liu et al., Radionuclide
131 I labeled
reduced graphene oxide for nuclear imaging guided combined radio- and photothermal
therapy of cancer. Biomaterials 66, 21–28 (2015)
4 Graphene-Based Nanomaterials
103